| Sequenom Charged With Faking It Derek Lowe submits: I wrote here about Sequenom (SQNM), a company which claimed to have developed an in vitro test for Downs Syndrome. The whole story dissolved into a heap of lawsuits, allegations of fraud, questions about whether Sequenom ever had such a test at all, and other craziness. Now the SEC has charged a former executive of the company with lying to investors. Elizabeth Dragon publicly touted the accuracy of the company's test several times, in front of large groups, before the roof came in. Here's the official complaint, and it's most interesting reading:Complete Story » seekingalpha.com |
5 Reasons Why Amarin Is My Top Buy Mike Havrilla submits:Amarin Corp. (NASDAQ:AMRN) is developing AMR101 (Ethyl-EPA) as a prescription-grade omega-3 fatty acid that has been marketed in Japan for over 10 years as EPADEL by Mochida Pharma (MCPMF.PK). Ethyl-EPA is differentiated from Glaxo's (NYSE:GSK) $1 billion dollar product LOVAZA (omega-3-acid ethyl esters) in the following key areas:no fishy smell/taste or GI side effects such as burping = better patient compliance since these are both taken every daylacks Ethyl-DHA omega-3 fatty acid component, which can raise bad cholesterol (LDL) levelspotential to address a much larger patient population including those with triglyceride levels of 200-500 mg/dL vs. LOVAZA, which is indicated for patients with triglyceride levels greater than 500 mg/dLAmarin is fully funded through a potential NDA filing with ongoing partnership discussions. My current estimate is for patient enrollment to conclude by late 2010 to early 2011 (ahead of the most recent company guidance) with results expected by mid-2011 under this scenario since both studies have 12-week treatment periods. It should also be noted that both studies are being conducted under Special Protocol Assessments with the FDA without the need for Phase 2 studies, supported by over 10 years of use in Japan and previous studies conducted by Amarin for a variety of neurological conditions. Complete Story » seekingalpha.com |
Hospital Bribe Alleged Prosecutors charged Alexander Everest with submitting forged documents and giving thousands of dollars in bribes to a hospital employee dealing with the residency applications. online.wsj.com |
China's Mindray Eyes U.S. While Western companies like GE and Philips sell expensive medical equipment in emerging markets, Chinese upstart Mindray is moving into their backyard with machines that cost 40% less than mainstream alternatives. online.wsj.com |
Cord Blood America Revenues Up 14 Percent in Third Quarter 2010 [PR Newswire] - Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, today said revenues for the third quarter ended September 30, 2010, increased 14 percent to $958,449 compared to $838,238 in the same period in 2009. Â us.rd.yahoo.com |